Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.
What we do:
Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry- leading contract research organisations to develop NCEs and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™.
- Acquisition, discovery and development of novel proprietary lead candidates.
- Repositioning FDA/EMA approved drugs.
- ALS (Lou Gehrig’s Disease)
- Other Neurological Diseases
- Addictive Behaviour
Clinical Accelerator conducts all phases of clinical trials for pharma, biotech and medtech companies. We have a very simple mission: to accelerate clinical development projects and to reduce their cost appreciably for our clients. We use several strategies to achieve very compact timelines in our clinical studies: - optimization of study design (only necessary outcome measures and end-points, right number of patients, optimal follow-up duration) - selection of effective investigative sites located in our region of operation. All our sites, conducting trials to the highest standards of GCP, have a large patient recruiting capacity and a proven track record of efficient timely recruitment of qualified patients. - accelerated start up (fast regulatory and IRB/EC approval times, streamlined logistics, expedited contracting, fast site activation, USA IND or EU CTA are optional in our region of operation) - effective patient enrolment and retention (dedicated department, proven region-specific patient recruitment strategies) We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines. We routinely rescue stalled clinical trials. We are able to reduce the cost of our clinical projects significantly due to our: - flat organizational hierarchy, reasonable service rates and very modest internal overhead costs - commitment to agreed fixed budgets (rare need for change orders) - modest investigator grants and low hospital overheads in our region of operation (very large savings can be achieved in many therapeutic areas) - use of as few locations and as few investigative sites as possible without compromising patient recruitment rates (this limits set-up costs and lowers per patient cost) - short study timelines, which lead to reduced management costs - potential risk sharing (optional strategy) The cost of our studies is among the most attractive globally. We commit to our budgets and fix them for our clients.
Clinical Network Services (CNS)
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Colliers International Group Inc. (NASDAQ and TSX: CIGI) is an industry-leading global real estate services company with 15,000 skilled professionals operating in 68 countries. Our services include strategic advice and execution for property sales, leasing and finance; global corporate solutions; property, facility and project management; workplace solutions; appraisal, valuation and tax consulting; customized research and thought leadership consulting.
Curileum Discovery Ltd is a new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.